PAVmed Inc. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
PAVmed reported Q2 2026 operating expenses of $7.1M and GAAP net loss of $5.5M ($0.87/share diluted). Lucid Diagnostics recognized $1.5M in EsoGuard revenue from 2,770 tests and secured first laboratory benefit manager coverage. Veris Health accelerated OSU-The James collaboration and advanced implantable physiological monitor toward early 2027 FDA 510(k) submission. Cash position improved to $3.8M as of June 30, 2026, from $1.5M at December 31, 2025.
Why this rating
Q2 revenue modest ($33K total); EsoGuard coverage policy meaningful but early-stage. Cash improvement material (153% gain) but $3.8M runway uncertain at $7.1M/quarter burn. FDA milestones progress positives offset by large quarterly losses relative to $7M market cap—company remains pre-profitability development stage.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.